Skip to content

Evaluation of the effect of Gaznab herbal product on the control of primary hypertension

Evaluation of the effect of adding Gaznab herbal product to standard treatment in patients with primary hypertension compared to placebo

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210622051660N1
Enrollment
36
Registered
2021-07-15
Start date
2021-07-17
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group: Gaznab syrup containing aqueous extract of jujube with a concentration of 15% w / v and nettle with a concentration of 10% w / v 2 times a day and each time 10 cc f

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Men and women aged 30-65 years Hypertension grade1 with pressure equal to or greater than 140.90 mmHg to 159.99 mmHg Are treated with a blood pressure medication (one to three drugs based on the protocol). BMI greater than or equal to 27 At least one month has passed since starting the medication The person should not be at high risk (diabetes mellitus and end organ damage , etc.)

Exclusion criteria

Exclusion criteria: History of hypo or hyperthyroidism Types of cardiac dysrhythmias (such as second and third degree block) Allergy to medicinal plants History of potassium greater than 5.1 or less than 3.5 m Eq / L at the first visit Warfarin consumption Pregnancy or lactation History of hypermenorrhea in females Presence of blood pressure greater than or equal to 180/110 mm Hg The presence of any medical or surgical disorder that could interfere with the study.

Design outcomes

Primary

MeasureTime frame
Blood pressure. Timepoint: In baseline and after 4 week and after 8 week. Method of measurement: Sphygmomanometer.;FBS, BUN, Cr, TG, Cholesterol, SGOT, SGPT, CBC. Timepoint: Beginning and end of the study (after 8 weeks). Method of measurement: Biochemical and Hematological blood check.

Secondary

MeasureTime frame
Quality of life score. Timepoint: pretest, post-test (at the end of 8 weeks). Method of measurement: The World Health Organization Quality of Life Questionnaire.;Stress, Anxiety and Depression score. Timepoint: pretest, post-test (at the end of 8 weeks). Method of measurement: DASS21 Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBatool Jalalkamali

Mashhad University of Medical Sciences

jalalkb1@mums.ac.ir+98 51 3891 0394

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026